Title : 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.

Pub. Date : 2010 Oct

PMID : 20847160






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 UNLABELLED: Targeting the mammalian target of rapamycin (mTOR) pathway is a potential means of overcoming cisplatin resistance in ovarian cancer patients. Cisplatin mechanistic target of rapamycin kinase Homo sapiens
2 UNLABELLED: Targeting the mammalian target of rapamycin (mTOR) pathway is a potential means of overcoming cisplatin resistance in ovarian cancer patients. Cisplatin mechanistic target of rapamycin kinase Homo sapiens
3 Because mTOR inhibition affects cell proliferation, we aimed to study whether 3"-deoxy-3"-(18)F-fluorothymidine ((18)F-FLT) PET could be useful for monitoring early response to treatment with mTOR inhibitors in an animal model of cisplatin-resistant ovarian tumor. Cisplatin mechanistic target of rapamycin kinase Homo sapiens
4 These data suggest that early treatment monitoring by (18)F-FLT PET may be of use in future preclinical or clinical trials evaluating treatment of cisplatin-resistant ovarian tumors by mTOR inhibitors. Cisplatin mechanistic target of rapamycin kinase Homo sapiens